TABLE 2.
Association of rs3798220-C Carrier Status With MACE and Major Bleeding Risk in the ASPREE Trial
| All Participants (N = 12,815) |
Placebo Arm (n = 6,439) |
Aspirin Arm (n = 6,376) |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Events | HR (95% CI) | P Value | Events | HR (95% CI) | P Value | Events | HR (95% CI) | P Value | |
| MACE | |||||||||
| rs3798220-C carriers | 435 (3.4) | 1.28 (0.80-2.06) | 0.29 | 243 (3.7) | 1.90 (1.11-3.24) | 0.018 | 192 (3.0) | 0.54 (0.17-1.71) | 0.29 |
| Pinteraction rs3798220-C * aspirin | 0.049 | ||||||||
| CSB | |||||||||
| rs3798220-C carriers | 395 (3.1) | 1.62 (0.47-5.60) | 0.508 | 169 (2.6) | 0.72 (0.27-1.92) | 0.508 | 226 (3.5) | 1.14 (0.54-2.41) | 0.736 |
| Pinteraction rs3798220-C * aspirin | 0.447 | ||||||||
Values are n (%), unless otherwise indicated.
ASPREE = ASPirin in Reducing Events in the Elderly; CSB = clinically significant bleeding; MACE = major adverse cardiovascular events.